Skip to content

Study · Randomized controlled trial · 2017

3 results

A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.

Buchanan RW, Kelly DL, Weiner E, Gold JM, Strauss GP, Koola MM, McMahon RP, Carpenter WT

Journal of clinical psychopharmacology1 Aug 2017Cited by 34 (Europe PMC)

PMID28590362 (opens in a new tab)PMCIDPMC5484721 (opens in a new tab)DOI10.1097/jcp.0000000000000720 (opens in a new tab)PepBankPUB-28590362
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with schizophrenia or schizoaffective disorder, intranasal oxytocin did not differ from placebo for negative symptoms.

    In plain wordsIn people with schizophrenia, oxytocin did not improve negative symptoms more than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeNegative symptoms (SANS total score)
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 6 weeksAs given in this study (human).

    Measurements

    P value
    0.83
    oxytocin vs placebo, negative symptoms

    Source sentences

    Summary
    There were no significant group differences for negative symptoms (oxytocin vs placebo: F2,47.4 = 0.19, P = 0.83
    2 context sentences
    Summary · context
    The Scale for the Assessment of Negative Symptoms total score was used to assess change in negative symptoms (the primary outcome measure for oxytocin).
    Summary · context
    Fifty-eight participants with either Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision schizophrenia or schizoaffective disorder entered into a 6-week double-blind, placebo-controlled, double-dummy, randomized clinical trial of intranasal oxytocin and galantamine.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with schizophrenia or schizoaffective disorder, intranasal oxytocin did not differ from placebo for cognitive impairments.

    In plain wordsIn people with schizophrenia, oxytocin did not improve thinking and memory more than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCognitive impairment (MATRICS composite)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 6 weeksAs given in this study (human).

    Measurements

    P value
    0.62
    oxytocin vs placebo, cognition

    Source sentences

    Summary
    There were no significant group differences for cognitive impairments (galantamine vs placebo: t40 = 0.71, P = 0.48; oxytocin vs placebo: t40 = 0.50, P = 0.62)
    1 context sentence
    Summary · context
    Fifty-eight participants with either Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision schizophrenia or schizoaffective disorder entered into a 6-week double-blind, placebo-controlled, double-dummy, randomized clinical trial of intranasal oxytocin and galantamine.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In people with schizophrenia or schizoaffective disorder, a trial of intranasal oxytocin and galantamine against placebo found no significant group differences for functional capacity or ancillary symptom measures.

    In plain wordsIn people with schizophrenia, there were no clear differences between groups in daily function or other symptom scores.

    Peptide
    Oxytocin
    Outcome
    No significant changeFunctional capacity and ancillary symptom measures
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    There were also no significant group differences for the functional capacity or ancillary symptom measures.
    1 context sentence
    Summary · context
    Fifty-eight participants with either Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision schizophrenia or schizoaffective disorder entered into a 6-week double-blind, placebo-controlled, double-dummy, randomized clinical trial of intranasal oxytocin and galantamine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.